EP0181213A2
Expired / Lapsed
EP
⏱️ 0.0 years remaining
Cephalosporium acremonium transformed with an aminoglycoside resistance marker
Assignee: Antibioticos SA
•
Filing: 1985-11-07
•
Granted: —
•
Expires: 2005-11-07
Abstract
Abstract The provision of Cephalosporium acremonium resistant to the aminoglycoside G418 allows the use of this aminoglycoside as a marker to select aminoglycoside-resistant cells of Cephalosporium acremonium from non-resistant cells of Cephalosporium acremonium. Aminoglycoside resistance can be imparted by transformation of Cephalosporium acremonium with a suitable vector.
Inventors
- 👤 A. Migual Penalva
- 👤 Angeles Tourino
- 👤 Cristina Patino
- 👤 Florentina Sanchez
- 👤 Victor Rubio
- 👤 Jose Maria Fernandez-Sousa
Bibliographic Details
Application Number
—
Jurisdiction
EP
Data Source
google_patents
Last Synchronized
2026-11-09 01:37
CPC Classifications
C; C12; C12N; C12N9/00; C12N9/10; C12N9/12; C12N15/00; C12N15/09; C12N15/63; C12N15/79; C12N15/80; Y; Y10; Y10S; Y10S435/00; Y10S435/8215; Y10S435/911; Y10S435/925; Y10S435/926
Claims Analysis
Total Claims: 15
Claim 1
Independent Claim
7 words
Cephalosporium acremonium with an aminoglycoside resistance marker.
Claim 2
Dependent Claim
7 words
Cephalosporium acremonium with an aminoglycoside resistance marker.
Claim 3
Dependent Claim
21 words
Cephalosporium acremonium according to claim 1, wherein said aminoglycoside is selected from the group consisting of G418 and neomycin resistance markers.
Claim 4
Dependent Claim
19 words
Cephalosporium acremonium according to claim 1, wherein said resistance is provided by a gene coding for an aminoglycoside 3'-phosphotransferase.
Claim 5
Dependent Claim
29 words
Cephalosporium acremonium according to claim 3, wherein said gene is selected from the genome of E. coli containing transposon Tn601(903), transposon Tn5, or from the genome of Streptomyces fradiae.
Claim 6
Dependent Claim
17 words
Cephalosporium acremonium according to claim 3, wherein transcription of said gene is promoted by a eukaryotic promoter.
Claim 7
Dependent Claim
23 words
Cephalosporium acremonium according to claim 5, wherein said eukaryotic promoter comprises the promoter of Saccharom y ces cerevisiae alcohol dehydrogenase I gene (ADCI).
Claim 8
Dependent Claim
12 words
A vector capable of transforming Cephalosporium acremonium with an aminoglycoside resistance gene.
Claim 9
Dependent Claim
12 words
A vector capable of transforming Cephalosporium acremonium with an aminoglycoside resistance gene.
Claim 10
Dependent Claim
30 words
A nucleic acid sequence substantially functionally homologous with plasmid pMA4 deposited at the National Collection of Industrial and Marine Bacteria on 1 November 1984 under the accession number NCIB 12025.
Claim 11
Dependent Claim
30 words
A nucleic acid sequence substantially functionally homologous with plasmid pMA4 deposited at the National Collection of Industrial and Marine Bacteria on 1 November 1984 under the accession number NCIB 12025.
Claim 12
Dependent Claim
31 words
A vector capable of transforming Cephalosporium acremonium to aminoglycoside resistance, said including a eukaryotic promoter and a non-eukaryotic gene coding for aminoglycoside resistance, said non-eukaryotic gene being transcribable from said promoter.
Claim 13
Dependent Claim
31 words
A vector capable of transforming Cephalosporium acremonium to aminoglycoside resistance, said including a eukaryotic promoter and a non-eukaryotic gene coding for aminoglycoside resistance, said non-eukaryotic gene being transcribable from said promoter.
Claim 14
Dependent Claim
21 words
The use of an aminoglycoside as a marker to select aminoglycoside-resistant cells of Cephalosporium acremonium from non-resistant cells of Cephalosporium acremonium.
Claim 15
Dependent Claim
21 words
The use of an aminoglycoside as a marker to select aminoglycoside-resistant cells of Cephalosporium acremonium from non-resistant cells of Cephalosporium acremonium.
References Cited (Backward Citations)
No citation records indexed.
USPTO Annuity & Maintenance Windows
Maintenance schedule is calculated for granted US utility patents.